AbbVie to acquire Pharmacyclics - MarketLine Financial Deals

AbbVie to acquire Pharmacyclics

AbbVie to acquire Pharmacyclics - MarketLine Financial Deals
AbbVie to acquire Pharmacyclics
Published Mar 04, 2015
4 pages — Published Mar 04, 2015
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

AbbVie, Inc. has signed a definitive agreement to acquire Pharmacyclics, Inc. and its flagship asset Imbruvica(R) (ibrutinib).

  
Source:
Document ID
MA154290_150311
Country
Ticker
ABBV=US
Ticker
PCYC=US
Company
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "AbbVie to acquire Pharmacyclics" Mar 04, 2015. Alacra Store. Dec 04, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/AbbVie-to-acquire-Pharmacyclics-2052-109684>
  
APA:
MarketLine Financial Deals. (2015). AbbVie to acquire Pharmacyclics Mar 04, 2015. New York, NY: Alacra Store. Retrieved Dec 04, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/AbbVie-to-acquire-Pharmacyclics-2052-109684>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.